benzbromarone has been researched along with Chemical and Drug Induced Liver Injury in 33 studies
Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.
benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.
Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Benzbromarone (BBR) is effective in the treatment of hyperuricemia, and has been used as an effective drug in Japan for a long time." | 4.95 | Strategic Drug Design to Avoid the Metabolic Activation of Hepatotoxic Drugs. ( Mashino, T; Nakamura, S; Ohe, T; Takahashi, K, 2017) |
| "Benzbromarone (BBR) is effective in the treatment of gout; however, clinical findings have shown it can also cause fatal hepatic failure." | 3.85 | Metabolic Epoxidation Is a Critical Step for the Development of Benzbromarone-Induced Hepatotoxicity. ( Lan, Q; Pang, J; Peng, Y; Wang, H; Wang, S; Wang, W; Wang, X; Zhang, T; Zhao, H; Zhao, Y; Zheng, J, 2017) |
| "A major adverse effect of benzbromarone is hepatotoxicity." | 1.62 | Implementation Status of Liver Function Tests for Monitoring Benzbromarone-Induced Hepatotoxicity: An Epidemiological Survey Using the Japanese Claims Database. ( Imai, S; Kashiwagi, H; Miyai, T; Momo, K; Nasuhara, Y; Oki, H; Sato, Y; Sugawara, M; Takekuma, Y, 2021) |
| "Treatment with benzbromarone can be associated with liver injury, but the detailed mechanism remains unknown." | 1.46 | Association of a reactive intermediate derived from 1',6-dihydroxy metabolite with benzbromarone-induced hepatotoxicity. ( Akita, H; Cho, N; Kobayashi, K; Yoshida, M, 2017) |
| "Benzbromarone is a uricosuric drug in current clinical use that can cause serious hepatotoxicity." | 1.43 | Inactivation of CYP3A4 by Benzbromarone in Human Liver Microsomes. ( Kondo, S; Masubuchi, Y, 2016) |
| " When compared with the same dosage of benzbromarone, UR-1102 showed a better pharmacokinetic profile, increased the fractional excretion of urinary uric acid, and reduced plasma uric acid more effectively." | 1.43 | Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone. ( Ahn, SO; Horiba, N; Kawabe, Y; Kim, BH; Kim, KH; Kiyokawa, J; Lee, KJ; Nakagawa, T; Ohtomo, S; Tanaka, J; Yamane, M, 2016) |
| "We describe a case of autoimmune hepatitis (AIH) that may have occurred following drug-induced liver injury with camostat mesilate and/or benzbromarone in an elderly patient." | 1.43 | Autoimmune hepatitis following drug-induced liver injury in an elderly patient. ( Arai, M; Haga, Y; Iino, Y; Kanda, T; Kumagai, J; Nakamoto, S; Nakamura, M; Sasaki, R; Wu, S; Yasui, S; Yokosuka, O, 2016) |
| "Benzbromarone (BBR) is a therapeutically useful uricosuric agent but can also cause acute liver injury." | 1.43 | Cysteine-Based Protein Adduction by Epoxide-Derived Metabolite(s) of Benzbromarone. ( Feng, Y; Guo, X; Huang, W; Peng, Y; Wang, H; Wang, Q; Zheng, J, 2016) |
| "Benzbromarone is an uricosuric structurally related to amiodarone and a known mitochondrial toxicant." | 1.40 | Hepatocellular toxicity of benzbromarone: effects on mitochondrial function and structure. ( Felser, A; Jenö, P; Krähenbühl, S; Kratschmar, DV; Lindinger, PW; Mies, S; Odermatt, A; Schnell, D, 2014) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| " An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems." | 1.36 | Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010) |
| "Benzbromarone (BBR) is a uricosuric agent that has been used as a treatment for chronic gout." | 1.34 | Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. ( McDonald, MG; Rettie, AE, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (12.12) | 18.2507 |
| 2000's | 3 (9.09) | 29.6817 |
| 2010's | 24 (72.73) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Greene, N | 1 |
| Fisk, L | 1 |
| Naven, RT | 1 |
| Note, RR | 1 |
| Patel, ML | 1 |
| Pelletier, DJ | 1 |
| Morgan, RE | 2 |
| Trauner, M | 1 |
| van Staden, CJ | 2 |
| Lee, PH | 1 |
| Ramachandran, B | 1 |
| Eschenberg, M | 1 |
| Afshari, CA | 2 |
| Qualls, CW | 1 |
| Lightfoot-Dunn, R | 1 |
| Hamadeh, HK | 2 |
| Ekins, S | 1 |
| Williams, AJ | 1 |
| Xu, JJ | 1 |
| Chen, M | 2 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 3 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Aleo, MD | 1 |
| Luo, Y | 1 |
| Swiss, R | 1 |
| Bonin, PD | 1 |
| Potter, DM | 1 |
| Will, Y | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Imai, S | 1 |
| Nasuhara, Y | 1 |
| Momo, K | 1 |
| Oki, H | 1 |
| Kashiwagi, H | 1 |
| Sato, Y | 1 |
| Miyai, T | 1 |
| Sugawara, M | 1 |
| Takekuma, Y | 1 |
| Cho, N | 2 |
| Suemizu, H | 1 |
| Kamimura, H | 1 |
| Ohe, T | 2 |
| Ito, F | 1 |
| Akita, H | 2 |
| Kobayashi, K | 2 |
| Yoshida, M | 1 |
| Wang, H | 2 |
| Peng, Y | 2 |
| Zhang, T | 1 |
| Lan, Q | 1 |
| Zhao, H | 1 |
| Wang, W | 1 |
| Zhao, Y | 1 |
| Wang, X | 1 |
| Pang, J | 1 |
| Wang, S | 1 |
| Zheng, J | 2 |
| Sun, P | 1 |
| Zhu, JJ | 1 |
| Wang, T | 1 |
| Huang, Q | 1 |
| Zhou, YR | 1 |
| Yu, BW | 1 |
| Jiang, HL | 1 |
| Wang, HY | 1 |
| Takemura, A | 1 |
| Gong, S | 1 |
| Sekine, S | 2 |
| Ito, K | 2 |
| Xu, Q | 1 |
| Liu, L | 1 |
| Vu, H | 1 |
| Kuhls, M | 1 |
| Aslamkhan, AG | 1 |
| Liaw, A | 1 |
| Yu, Y | 1 |
| Kaczor, A | 1 |
| Ruth, M | 1 |
| Wei, C | 1 |
| Imredy, J | 1 |
| Lebron, J | 1 |
| Pearson, K | 1 |
| Gonzalez, R | 1 |
| Mitra, K | 1 |
| Sistare, FD | 1 |
| Felser, A | 1 |
| Lindinger, PW | 1 |
| Schnell, D | 1 |
| Kratschmar, DV | 1 |
| Odermatt, A | 1 |
| Mies, S | 1 |
| Jenö, P | 1 |
| Krähenbühl, S | 1 |
| Shirakawa, M | 1 |
| Tanaka, A | 1 |
| Horie, T | 1 |
| Masubuchi, Y | 1 |
| Kondo, S | 1 |
| Ahn, SO | 1 |
| Ohtomo, S | 1 |
| Kiyokawa, J | 1 |
| Nakagawa, T | 1 |
| Yamane, M | 1 |
| Lee, KJ | 1 |
| Kim, KH | 1 |
| Kim, BH | 1 |
| Tanaka, J | 1 |
| Kawabe, Y | 1 |
| Horiba, N | 1 |
| Kumagai, J | 1 |
| Kanda, T | 1 |
| Yasui, S | 1 |
| Haga, Y | 1 |
| Sasaki, R | 1 |
| Nakamura, M | 1 |
| Wu, S | 1 |
| Nakamoto, S | 1 |
| Arai, M | 1 |
| Iino, Y | 1 |
| Yokosuka, O | 1 |
| Feng, Y | 1 |
| Wang, Q | 1 |
| Guo, X | 1 |
| Huang, W | 1 |
| Takahashi, K | 1 |
| Nakamura, S | 1 |
| Mashino, T | 1 |
| Lee, MH | 1 |
| Graham, GG | 1 |
| Williams, KM | 1 |
| Day, RO | 1 |
| Matsumoto, K | 1 |
| Haring, B | 1 |
| Kudlich, T | 1 |
| Rauthe, S | 1 |
| Melcher, R | 1 |
| Geier, A | 1 |
| McDonald, MG | 1 |
| Rettie, AE | 1 |
| Hautekeete, ML | 1 |
| Henrion, J | 1 |
| Naegels, S | 1 |
| DeNeve, A | 1 |
| Adler, M | 1 |
| Deprez, C | 1 |
| Devis, G | 1 |
| Klöppel, G | 1 |
| Gehenot, M | 1 |
| Horsmans, Y | 1 |
| Rahier, J | 2 |
| Geubel, AP | 2 |
| van der Klauw, MM | 1 |
| Houtman, PM | 1 |
| Stricker, BH | 1 |
| Spoelstra, P | 1 |
| Suzuki, T | 2 |
| Kimura, M | 1 |
| Shinoda, M | 1 |
| Fujita, T | 1 |
| Miyake, N | 1 |
| Yamamoto, S | 1 |
| Tashiro, K | 1 |
| Nakad, A | 1 |
| Azzouzi, K | 1 |
| Gerbaux, A | 1 |
| Delcourt, A | 1 |
| Sempoux, C | 1 |
| Tamo, F | 1 |
5 reviews available for benzbromarone and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Strategic Drug Design to Avoid the Metabolic Activation of Hepatotoxic Drugs.
Topics: Benzbromarone; Catechols; Cell Survival; Chemical and Drug Induced Liver Injury; Cytochrome P-450 En | 2017 |
A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?
Topics: Animals; Benzbromarone; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Appro | 2008 |
[Drug-induced hepatic injury, the challenge for cause investigation].
Topics: Animals; Apoptosis; Benzbromarone; Cells, Cultured; Chemical and Drug Induced Liver Injury; Chromans | 2011 |
[A case of fulminant hepatitis, possibly caused by benzbromarone].
Topics: Alprostadil; Benzbromarone; Chemical and Drug Induced Liver Injury; Hemodiafiltration; Humans; Male; | 2001 |
28 other studies available for benzbromarone and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2014 |
Implementation Status of Liver Function Tests for Monitoring Benzbromarone-Induced Hepatotoxicity: An Epidemiological Survey Using the Japanese Claims Database.
Topics: Administrative Claims, Healthcare; Adolescent; Adult; Aged; Benzbromarone; Chemical and Drug Induced | 2021 |
Formation of reactive metabolites of benzbromarone in humanized-liver mice.
Topics: Animals; Benzbromarone; Chemical and Drug Induced Liver Injury; Hepatocytes; Humans; Liver; Mice; Mi | 2022 |
Association of a reactive intermediate derived from 1',6-dihydroxy metabolite with benzbromarone-induced hepatotoxicity.
Topics: Animals; Benzbromarone; Chemical and Drug Induced Liver Injury; Liver; Male; Mice; Mice, Inbred ICR; | 2017 |
Metabolic Epoxidation Is a Critical Step for the Development of Benzbromarone-Induced Hepatotoxicity.
Topics: Activation, Metabolic; Animals; Benzbromarone; Chemical and Drug Induced Liver Injury; Cytochrome P- | 2017 |
Benzbromarone aggravates hepatic steatosis in obese individuals.
Topics: Adult; Aged; Animals; Apoptosis; Benzbromarone; Chemical and Drug Induced Liver Injury; Diet, High-F | 2018 |
Inhibition of biliary network reconstruction by benzbromarone delays recovery from pre-existing liver injury.
Topics: Alanine Transaminase; Animals; Benzbromarone; Cells, Cultured; Chemical and Drug Induced Liver Injur | 2019 |
Can Galactose Be Converted to Glucose in HepG2 Cells? Improving the
Topics: Amiodarone; Benzbromarone; Chemical and Drug Induced Liver Injury; Galactose; Glucose; Hep G2 Cells; | 2019 |
Hepatocellular toxicity of benzbromarone: effects on mitochondrial function and structure.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Benzbromarone; Chemical and Drug Induced Liver Injury; D | 2014 |
Metabolic activation of hepatotoxic drug (benzbromarone) induced mitochondrial membrane permeability transition.
Topics: Activation, Metabolic; Animals; Benzbromarone; Chemical and Drug Induced Liver Injury; Cytochrome P- | 2015 |
Inactivation of CYP3A4 by Benzbromarone in Human Liver Microsomes.
Topics: Benzbromarone; Biotransformation; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A; Cy | 2016 |
Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
Topics: Animals; Benzbromarone; Cebus; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, D | 2016 |
Autoimmune hepatitis following drug-induced liver injury in an elderly patient.
Topics: Aged; Benzbromarone; Biopsy; Chemical and Drug Induced Liver Injury; Esters; Gabexate; Guanidines; H | 2016 |
Cysteine-Based Protein Adduction by Epoxide-Derived Metabolite(s) of Benzbromarone.
Topics: Animals; Benzbromarone; Chemical and Drug Induced Liver Injury; Cysteine; Epoxy Compounds; Glutathio | 2016 |
Benzbromarone: a double-edged sword that cuts the liver?
Topics: Aged; Benzbromarone; Biopsy; Chemical and Drug Induced Liver Injury; Disease Progression; Fatal Outc | 2013 |
Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Catechols; Chemical and Dr | 2007 |
Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities.
Topics: Adult; Aged; Benzbromarone; Biopsy; Chemical and Drug Induced Liver Injury; Chemical and Drug Induce | 1995 |
Subfulminant hepatitis requiring liver transplantation after benzarone administration.
Topics: Benzbromarone; Chemical and Drug Induced Liver Injury; Female; Hepatic Encephalopathy; Humans; Liver | 1994 |
Hepatic injury caused by benzbromarone.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Benzbromarone; Chemical and Drug Induced Li | 1994 |
[Hepatitis caused by benzarone: a second case].
Topics: Aged; Benzbromarone; Chemical and Drug Induced Liver Injury; Female; Fibrinolytic Agents; Humans | 1990 |